State Street Corp Raises Stake in XBiotech Inc. (NASDAQ:XBIT)

State Street Corp lifted its position in XBiotech Inc. (NASDAQ:XBIT) by 10.7% in the third quarter, HoldingsChannel.com reports. The firm owned 224,595 shares of the biopharmaceutical company’s stock after purchasing an additional 21,752 shares during the quarter. State Street Corp’s holdings in XBiotech were worth $1,736,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in XBiotech by 2.2% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 253,770 shares of the biopharmaceutical company’s stock worth $1,962,000 after buying an additional 5,500 shares in the last quarter. MetLife Investment Management LLC purchased a new stake in shares of XBiotech during the third quarter worth about $94,000. BNP Paribas Financial Markets raised its stake in XBiotech by 184.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 40,040 shares of the biopharmaceutical company’s stock valued at $310,000 after purchasing an additional 25,987 shares during the period. FMR LLC lifted its holdings in XBiotech by 34.4% in the 3rd quarter. FMR LLC now owns 28,992 shares of the biopharmaceutical company’s stock worth $224,000 after purchasing an additional 7,420 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in XBiotech by 7.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 58,437 shares of the biopharmaceutical company’s stock worth $452,000 after purchasing an additional 4,298 shares in the last quarter. 55.70% of the stock is currently owned by institutional investors.

XBiotech Price Performance

XBiotech stock opened at $3.95 on Thursday. XBiotech Inc. has a 1 year low of $3.51 and a 1 year high of $9.96. The firm’s 50 day moving average price is $6.54 and its 200-day moving average price is $6.54. The stock has a market cap of $120.41 million, a P/E ratio of -3.66 and a beta of 1.41.

About XBiotech

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.